Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
07 September 2023 - 8:30PM
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, announced today that its Chief Executive Officer, Dr.
Adi Hoess, will present at the H.C. Wainwright 25th Annual Global
Investment Conference on Tuesday, September 12, 2023 at 11:00 a.m.
Eastern Daylight Time / 17:00 Central European Time.
A live webcast of the presentation will be accessible on
Affimed’s website
at https://www.affimed.com/investors/webcasts-and-corporate-presentation/.
A replay of the call will be archived on Affimed’s website for 30
days after the call.
For more information on the conference or to schedule a
one-on-one meeting with Affimed management, please contact your
conference representative, or Alex Fudukidis via email at
a.fudukidis@affimed.com or phone at +1 (917) 436-8102.
About Affimed N.V.Affimed
(Nasdaq: AFMD) is a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer by actualizing the untapped potential of the innate immune
system. The Company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the Company’s
people, pipeline and partners, please visit: www.affimed.com.
Affimed Investor ContactAlexander
FudukidisDirector, Head of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2024 to May 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From May 2023 to May 2024